Fertiprotekt

Fertiprotekt is a German-founded cooperation of university centers, hospitals, and medical practices focused on fertility preservation for people facing chemotherapy, radiotherapy, or other treatments that may impair reproductive function. Established in 2006, the network was created in response to the growing importance of long-term quality of life among cancer survivors. As survival rates for many cancers improved, the possibility of infertility, premature ovarian insufficiency, or permanent testicular damage became an increasingly important part of treatment planning for younger patients. The network’s central role is to connect patients with scientific counseling and fertility-preserving procedures. Its work covers both women and men and is intended to support decisions before cancer treatment begins, while also addressing fertility-related questions after treatment. The participating institutions operate under a network code of ethics and provide counseling and procedures on a nonprofit-oriented basis. Fertiprotekt is not presented as a conventional consumer healthcare brand or a single clinic; it is a coordinated medical network intended to create consistent standards and access across German-speaking countries. Its clinical scope includes established options such as sperm cryopreservation and assisted reproductive procedures, as well as techniques that have developed more recently or remain specialized. Depending on the patient’s circumstances, these can include ovarian stimulation followed by cryopreservation of fertilized or unfertilized oocytes, ovarian-tissue cryopreservation, ovarian transposition before radiotherapy, and the use of gonadotropin-releasing hormone agonists. For men, preservation of sperm and, in selected cases, testicular tissue are relevant approaches. The choice of method depends on age, diagnosis, treatment urgency, reproductive goals, and the time available before cancer therapy. Fertiprotekt has also contributed to the development of coordinated care structures and treatment recommendations. The network is associated with the introduction and wider use of luteal-phase stimulation, which allows oocyte stimulation to begin at different points in the menstrual cycle and can reduce delays before chemotherapy. Its participating centers have also combined ovarian-tissue cryopreservation with subsequent hormonal stimulation and oocyte cryopreservation, an approach intended to broaden the chances of future fertility. Another reported achievement involved the transport of removed ovarian tissue to a central cryobank shortly after surgery, followed by preparation and storage in a specialized facility; this work supported the feasibility of centralized tissue handling and was associated with a first birth after ovarian-tissue transposition. The network’s activities include annual seminars and conferences, with participating centers expected to take part regularly. These meetings support professional exchange, maintenance of common standards, and continuing development of recommendations. Fertiprotekt’s network model has been described as an international pioneering effort because it created comprehensive national structures for fertility preservation rather than leaving care fragmented among individual hospitals and practices. Its services exist within a changing healthcare and reimbursement environment. Some procedures, including sperm cryopreservation and in-vitro fertilization, are well established, while ovarian-tissue and unfertilized-oocyte cryopreservation have historically been newer and less consistently covered by statutory health insurance in Germany. Consequently, access and reimbursement can vary according to the procedure, indication, insurer, and applicable rules. The network’s public significance lies in integrating medical advice, preservation techniques, scientific recommendations, and specialist referral pathways for patients whose cancer treatment may threaten future fertility.

Fertiprotekt was established in Germany in 2006 as a cooperation among university centers, hospitals, and medical practices. Its formation reflected a clinical need created by improving cancer survival: patients who survived treatment increasingly required support for long-term quality of life, including the possibility of preserving reproductive potential before therapy. The network developed a coordinated structure for fertility preservation in a field that had previously been distributed among individual specialists and institutions. Its purpose was to make scientific counseling and fertility-preserving procedures available through a national network while encouraging common standards and ethical, nonprofit-oriented practice. The focus included women and men who were preparing for chemotherapy or radiotherapy, as well as patients seeking advice after treatment. Over time, Fertiprotekt expanded beyond Germany to include institutions in Austria and Switzerland. The network has been described as comprising approximately 100 participating institutions across the three countries. Its activities include regular seminars and annual conferences, with member centers expected to participate. These meetings provide a mechanism for sharing clinical experience, reviewing treatment recommendations, and maintaining a common professional framework. The network’s clinical and scientific work has covered several fertility-preservation methods. Established approaches include sperm cryopreservation and in-vitro fertilization, while other procedures became more widely available as reproductive medicine advanced. These include cryopreservation of unfertilized oocytes, ovarian-tissue cryopreservation before cancer treatment, and ovarian transposition to move the ovaries away from a radiotherapy field. The network also supported the use of hormonal stimulation methods designed to reduce the delay between fertility-preservation treatment and the beginning of chemotherapy. One notable development associated with the network was the introduction of luteal-phase stimulation. Because stimulation can begin at different stages of the menstrual cycle, patients may be able to undergo oocyte collection more rapidly than with protocols tied to the start of a conventional cycle. This is particularly relevant in oncology, where postponing cancer treatment may be undesirable. Fertiprotekt centers also performed a combination of ovarian-tissue cryopreservation followed directly by hormonal stimulation and oocyte collection, seeking to increase the number of preserved reproductive materials within the limited time available before treatment. The network further demonstrated the feasibility of transporting removed ovarian tissue to a central cryobank shortly after surgery, where it could be processed and stored by specialized personnel. This work was linked to the first birth after transposition of ovarian tissue and illustrated how decentralized surgery could be combined with centralized tissue preparation and storage. Fertiprotekt operates in a field where clinical evidence, regulation, and insurance reimbursement continue to evolve. Sperm preservation and IVF are comparatively established, whereas ovarian-tissue and unfertilized-oocyte preservation were newer services and were not always fully reimbursed by statutory health insurance in Germany. The network therefore combines clinical coordination with professional education and the development of recommendations intended to support consistent decision-making. Its historical contribution is primarily institutional: it helped build a cross-regional fertility-preservation infrastructure for oncology patients in German-speaking Europe.

• 2006

  Network founded in Germany

  [1]Fertiprotekten.wikipedia.org

  Fertiprotekt was established as a cooperation among university centers, hospitals, and medical practices to coordinate fertility-preservation care for patients facing potentially fertility-damaging cancer treatment.

• Expansion across German-speaking Europe

  [1]Fertiprotekten.wikipedia.org

  The network expanded to institutions in Germany, Austria, and Switzerland, ultimately linking approximately 100 participating centers according to the cited reference material.

• Luteal-phase stimulation introduced

  [1]Fertiprotekten.wikipedia.org

  Participating centers introduced luteal-phase stimulation, allowing ovarian stimulation to begin at different points in the menstrual cycle and potentially shortening the interval before chemotherapy.

• Integrated ovarian-tissue and oocyte preservation approach

  [1]Fertiprotekten.wikipedia.org

  Centers in the network combined ovarian-tissue cryopreservation with immediate hormonal stimulation and oocyte collection, an approach intended to increase the amount of reproductive material preserved before cancer treatment.

• Centralized ovarian-tissue cryostorage demonstrated

  [1]Fertiprotekten.wikipedia.org

  The network was associated with transporting ovarian tissue to a central cryobank for preparation and storage and with a first birth after ovarian-tissue transposition.

A nonprofit-oriented, evidence-based medical network that coordinates fertility-preservation counseling and procedures across German-speaking Europe, with an emphasis on standardized care and specialist cooperation.

• Medical counseling

  Oncology fertility-preservation counseling

  Specialist counseling for women and men before or after chemotherapy and radiotherapy. The service addresses expected effects on ovarian, testicular, and reproductive function, available preservation methods, treatment timing, and possible future reproductive options.

• Reproductive medicine

  Oocyte and embryo cryopreservation

  Fertility-preservation procedures involving ovarian stimulation and the collection of oocytes, which may be frozen unfertilized or fertilized for later use. These procedures are coordinated with oncology treatment schedules and are selected according to the patient’s medical and reproductive circumstances.

• Tissue preservation

  Ovarian-tissue cryopreservation

  Surgical removal and cryopreservation of ovarian tissue before potentially gonadotoxic treatment. The tissue can be prepared and stored in a specialized facility, with later transplantation considered in suitable cases.

• Male fertility preservation

  Sperm preservation

  Cryopreservation of sperm before cancer treatment that could permanently damage testicular function. It is among the more established fertility-preservation options and may be coordinated through participating clinics and reproductive-medicine facilities.

• Radiotherapy protection

  Ovarian transposition

  A surgical procedure that relocates the ovaries away from the planned radiation field in order to reduce treatment-related damage. It is considered in selected patients whose cancer therapy involves pelvic or nearby radiotherapy.

1. 1Fertiprotekten.wikipedia.org
2. 2FertiPROTEKT official websitefertiprotekt.com